Aphthosin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Others |
| Catalog number | BBF-05132 |
| CAS | 31449-13-5 |
| Molecular Weight | 646.59 |
| Molecular Formula | C34H30O13 |
Online Inquiry
Description
Aphthosin is a tetrapeptide glycoside isolated from Peltigera aphthosa (L.) Willd.
Specification
| Synonyms | 2,6-Cresotic acid, 4-methoxy-, 4-ester with 6-methyl-β-resorcylic acid, 4-ester with 6-methyl-β-resorcylic acid, 4-ester with methyl 6-methyl-β-resorcylate (8CI) |
| IUPAC Name | [3-hydroxy-4-[3-hydroxy-4-(3-hydroxy-4-methoxycarbonyl-5-methylphenoxy)carbonyl-5-methylphenoxy]carbonyl-5-methylphenyl] 2-hydroxy-4-methoxy-6-methylbenzoate |
| Canonical SMILES | CC1=CC(=CC(=C1C(=O)OC2=CC(=C(C(=C2)C)C(=O)OC3=CC(=C(C(=C3)C)C(=O)OC4=CC(=C(C(=C4)C)C(=O)OC)O)O)O)O)OC |
| InChI | InChI=1S/C34H30O13/c1-15-7-19(43-5)11-23(35)28(15)32(40)46-21-9-17(3)30(25(37)13-21)34(42)47-22-10-18(4)29(26(38)14-22)33(41)45-20-8-16(2)27(24(36)12-20)31(39)44-6/h7-14,35-38H,1-6H3 |
| InChI Key | VIOAANSIBLJPLO-UHFFFAOYSA-N |
Properties
| Boiling Point | 768.8±60.0°C (Predicted) |
| Density | 1.404±0.06 g/cm3 (Predicted) |
Reference Reading
1. Recurrent aphtous stomatitis
Luca Giannetti, Alberto Murri Dello Diago, Lorenzo Lo Muzio Minerva Stomatol. 2018 Jun;67(3):125-128. doi: 10.23736/S0026-4970.18.04137-7. Epub 2018 Jan 11.
Recurrent aphtous stomatitis (recurrent aphtous ulcers, canker sores) is the most common ulcerative disease of the oral mucosa. In this paper we presented the main clinical features, epidemiologic data, etiopathogenetic factors and clinical management, based on the current medical literature reports.
2. Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options
Charles B Lau, Gideon P Smith Dermatol Ther. 2022 Jun;35(6):e15500. doi: 10.1111/dth.15500. Epub 2022 Apr 18.
Recurrent aphthous stomatitis (RAS) is a common chronic disease in the oral mucosa that affects about 20% of the population. It is characterized by solitary or multiple, recurrent, small ulcers with erythematous haloes and yellow/gray floors. RAS can be managed through a wide variety of preventative measures and therapies, intending to reduce ulcer pain, stimulate ulcer healing, and/or prevent ulcer recurrence. First-line treatment options include topical medications in the form of corticosteroids (triamcinolone acetonide), anti-inflammatory drugs (amlexanox), antibiotics (doxycycline), and antiseptics (lidocaine). In more severe cases of RAS where local treatment is insufficient, systemic drugs in the form of corticosteroids (prednisone), immunomodulatory drugs (thalidomide), and antibiotics/antimicrobials (clofazimine) can prove effective. This review will summarize current treatment options for RAS with discussion of prevention, topical measures, natural treatments, systemic therapies, and new potential therapies. Furthermore, this review will provide recommendations on therapeutic options for RAS based on disease severity and patient circumstances.
3. Oral Aphthous: Pathophysiology, Clinical Aspects and Medical Treatment
A Gasmi Benahmed, S Noor, A Menzel, A Gasmi Arch Razi Inst. 2021 Nov 30;76(5):1155-1163. doi: 10.22092/ari.2021.356055.1767. eCollection 2021 Nov.
Oral aphthosis is a painful inflammatory process of the oral mucosa. Oral aphthous can appear alone or secondary to numerous distinct disease processes. If recurrence occurs frequently, it is called recurrent aphthous stomatitis. The pathophysiology of oral aphthous ulcers remains unclear but various bacteria are part of its microbiology. Three morphological types hold great importance in literature because these types help manage the illness properly. Google Scholar and PubMed databases were used to retrieve the relevant data and information. Different keywords including "Aphthous", "Aphthosis", "Canker sores", "Aphthous stomatitis", "Aphthous ulcer causes", "Aphthous ulcer AND Microbiota" and "Aphthous ulcer AND treatment". The causes for oral aphthous ulcerations are widespread and ranges from localized trauma to rare syndromes, underlying intestinal disease, or even malignant disease processes. A detailed history and thorough examination of systems can assist the physician or dermatologist in defining whether it is related to a systemic disease process or truly idiopathic. Management of oral aphthous ulcers is challenging. For oral aphthous or recurrent aphthous ulcers from an underlying disease, topical medications are preferred due to their minimum side effects. Systemic medications are necessary if the disease progresses. Within the limitation of research and literature provided, it is safe to say that topical corticosteroids are the first line of treatment. Herein, the author discusses the pathophysiology, types, causes, diagnosis, and appropriate treatment ladder of oral aphthous stomatitis as described in the literature.
Recommended Products
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
